Most Popular

Most Popular News
January 27, 2018

The expression of endogenous retroviruses in tumors appears to be a major mechanism of immunogenicity and can predict responses to PD-1 blockade in clear-cell renal cell carcinoma, according to a new study.

Read more

January 27, 2018

A subset of patients with early-stage prostate cancer characterized by certain gene expression are at an increased risk of developing metastatic disease, and present with targetable immune biology. 

Read more
January 27, 2018

Experts discussed how as the field of immunotherapy matures, new targets, combinations, and concepts have begun to emerge, with particular interest in expanding the uses of immunotherapy into malignancies that have so far proven largely resistant to the approach. 

Read more

January 27, 2018

A novel approach to CAR T-cell therapy involving a trivalent design targeting CD19, CD20, and CD22 can effectively target primary acute lymphoblastic leukemia (ALL) cells, and could potentially mitigate CD19-negative relapse, according to a new laboratory study.

Read more

January 27, 2018

A CD19-directed CAR T-cell therapy known as JCAR017 showed potent and durable responses in a study of patients with poor-prognosis relapsed or refractory non-Hodgkin lymphoma.

Read more

January 26, 2018

The combination of a selective PARP inhibitor known as pamiparib (BGB-290) and an agent targeting the PD-1 receptor known as tislelizumab (BGB-A317) was well tolerated with activity that supports continued investigation, according to a phase I trial in patients with advanced malignancies.

Read more

January 26, 2018

A first-in-class agent known as E7046 that inhibits the PGE2-receptor type 4 was well tolerated and showed promising clinical activity, especially regarding its potential for combination therapy, in a phase I trial of patients with advanced malignancies.

Read more

January 26, 2018

Treatment with multisite stereotactic body radiotherapy prior to pembrolizumab treatment may help improve outcomes in patients with advanced solid tumors and multiple metastatic sites, according to a phase I study.

Read more
January 23, 2018

Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO-sponsored or cosponsored meeting and recognized for its scientific merit.

Read more
January 18, 2018

Women in oncology aren’t ascending the leadership ladder at rates anywhere close to their male counterparts—and ASCO wants to fix that.

Read more
January 18, 2018

CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has signed formal collaboration agreements with seven other nonprofit associations and two federal agencies.

Read more
January 18, 2018

The most common malignancies that metastasize to the brain are melanoma and non–small cell lung cancer.

Read more
January 18, 2018

ASCO's TAPUR Study continues to expand and now has more than 450 participants enrolled on study drug, new partnerships, and a revised protocol to lower the age of eligibility, and will soon have more than 100 sites.

Read more
January 18, 2018

Dr. Jalil Ali and Dr. Layth Mula-Hussain are two of the oncologists determined to revive cancer care progress in Iraq.

Read more

January 18, 2018

Development of therapies for patients with rare tumors can be challenging due to small patient sizes and lack of phase III trials.

Read more
January 18, 2018

A new guideline from ASCO outlines best practices for cancer clinicians when communicating with patients and their loved ones.

Read more
January 18, 2018

The ASCO clinical practice guideline stresses that health care providers need to initiate the discussion about sexual function with their patients as early as possible in the treatment paradigm.

Read more

January 18, 2018

Dr. Jeffrey A. Bluestone, president and CEO of the Parker Institute for Cancer Immunotherapy, will provide an overview of past developments in cancer immunotherapy and discuss the future of research in this field in his keynote lecture on January 25.

Read more

January 18, 2018

Internationally renowned clinical scientist Malcolm K. Brenner, MD, PhD, will provide an overview of recent advances in the development of cellular therapies for cancer during his keynote lecture, “Cellular Therapy for Cancer.”

Read more

January 18, 2018

Dr. Mary L. Disis and Dr. Kunle Odunsi discuss the latest developments in immunotherapy for gynecologic cancers and its future promise.

Read more